Phase_II_trial_of_interferon_gamma_and_monoclonal_antibody_17-1A_in_pancreatic_cancer:_biologic_and_clinical_effects._Thirty_patients_with_advanced_measurable_pancreatic_adenocarcinoma_were_entered_onto_a_phase_II_trial_with_recombinant_interferon_gamma_(Biogen,_Cambridge,_MA;_10(6)_U/m2_daily_for_4_days)_and_monoclonal_antibody_(Mab)_17-1A_(Centocor,_Malvern,_PA;_150_mg_in_autologous_leukocytes_on_days_2,_3,_and_4_following_interferon_infusion)._The_effect_of_a_single_interferon_gamma_treatment_on_natural_and_antibody-dependent_cellular_cytotoxicity_(ADCC),_Fc_receptor_occupancy_by_antibody,_and_human_leukocyte_antigen-DR_(HLA-DR)_expression_on_monocytes_and_lymphocytes_was_also_studied._Toxicity_was_modest_and_generally_limited_to_grade_I_to_II_fever,_nausea_and_vomiting,_and_hepatotoxicity._Five_patients_were_considered_to_be_nonassessable_for_response._Of_the_25_assessable_patients,_one_objective_response_(complete_remission_for_a_duration_of_4_months)_was_observed._Stable_disease_for_2_months_or_greater_was_noted_in_nine_patients._The_median_survival_for_the_group_was_5_months._Analysis_of_cytotoxicity_data_obtained_prior_to_treatment_showed_reduced_natural_cytotoxic_activity_in_these_patients_compared_with_normal_volunteers._A_significant_improvement_in_natural_cytotoxic_activity_to_normal_levels_occurred_within_24_hours_following_the_interferon_gamma_infusion._This_was_also_associated_with_augmented_antibody-dependent_cellular_cytotoxicity._Although_HLA-DR_expression_was_not_increased_on_either_monocytes_or_lymphocytes,_an_increased_capacity_of_both_lymphocytes_and_monocytes_to_bind_Mab_17-1A_was_observed._In_all_in_vitro_assays_of_ADCC,_the_presence_of_antibody_excess_was_associated_with_improved_cytolytic_activity._In_spite_of_the_favorable_modulation_of_cytolytic_activity_and_improved_ability_of_effector_cells_to_bind_Mab,_we_failed_to_demonstrated_adequate_clinical_efficacy_in_the_treatment_of_patients_with_pancreatic_adenocarcinoma_using_this_dose_and_schedule_of_interferon_gamma_and_Mab_17-1A._Future_trials_will_focus_on_alternate_schedules_of_Mab_17-1A_with_the_hope_of_improving_tumor_antigen_saturation_and_circulating_levels_of_infused_antibody.